Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
US-2015266959-A1 · Sep 24, 2015 · US
Depleting tumor-specific tregs
US10087259B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-10087259-B1 |
| Application number | US-201514698600-A |
| Country | US |
| Kind code | B1 |
| Filing date | Apr 28, 2015 |
| Priority date | Apr 28, 2014 |
| Publication date | Oct 2, 2018 |
| Grant date | Oct 2, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides, among other things, methods and compositions for diagnosing and/or treating cancer by targeting CCR8. In particular, the present invention provides technologies for depleting Treg cells, and particularly tumor-infiltrating Treg cells.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating cancer by administering to a cancer patient who has a tumor in which CCR8 on tumor-infiltrating Treg cells is overexpressed relative to its level on circulating blood Treg cells, an antibody agent comprising CDRs of an antibody that binds specifically to CCR8 so that the antibody agent binds specifically to CCR8 and tumor-infiltrating Treg cells are specifically depleted in the subject, to a greater extent than are normal-tissue infiltrating T-cells. 2. The method of claim 1 , wherein the CCR8-targeting antibody agent comprises a payload moiety that, when delivered to tumor-infiltrating Treg cells, depletes such cells from the tumor. 3. The method of claim 1 , which method further comprises targeting CCR4. 4. The method of claim 3 , wherein targeting CCR4 comprises administering to the subject a composition comprising a CCR4-targeting antibody agent. 5. The method of claim 4 , wherein the CCR4-targeting antibody agent is or comprises a bifunctional antibody agent that targets both CCR8 and CCR4. 6. The method of claim 1 , further comprising administering one or more immunomodulatory therapeutic modalities to the subject.
Assignees
Inventors
Classifications
- G01N33/5759Primary
involving compounds localised on the membrane of tumour or cancer cells · CPC title
- G01N33/57505Primary
of the blood, e.g. leukaemia · CPC title
comprising antibodies · CPC title
for chemokines · CPC title
multispecific · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10087259B1 cover?
- The present invention provides, among other things, methods and compositions for diagnosing and/or treating cancer by targeting CCR8. In particular, the present invention provides technologies for depleting Treg cells, and particularly tumor-infiltrating Treg cells.
- Who is the assignee on this patent?
- Memorial Sloan Kettering Cancer Center
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5759. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).